Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis

Journal of Immunology

Volumn 164, Issue 1, 2000, Pages 217-222

  Fathallah Shaykh, Hassan M ^a,b   Zhao, Li Juan ^a   Kafrouni, Abdallah I ^a   Smith, George M ^a   Forman, James ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA GALACTOSIDASE; COMPLEMENTARY DNA; GAMMA INTERFERON; MATRIGEL; NITRIC OXIDE SYNTHASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CONTROLLED STUDY; GENE TRANSFER; KNOCKOUT MOUSE; LEWIS CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL TIME; TEMPERATURE SENSITIVE MUTANT; TUMOR REJECTION; TUMOR VASCULARIZATION;

EID: 0033957424     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.1.217     Document Type: Article

References (18)

1. Fathallah-Shaykh, H. 1999. New molecular strategies to cure brain tumors. Arch. Neurol. 56:449.
2. Fathallah-Shaykh, H. M., and D. D. McIntire. 1998. Brain tumors in the elderly: undefeated and gaining grounds. Arch. Neurol. 55:905.
3. Folkman, J. 1992. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3:65.
4. Folkman, J., and D. Ingber. 1992. Inhibition of angiogenesis. Semin. Cancer Biol. 3:89.
5. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353.
6. Fathallah-Shaykh, H. M., W. Gao, M. Cho, and M. A. Herrera. 1998. Priming in the brain, an immunologically-privileged organ, elicits anti-tumor immunity. Int. J. Cancer 75:266.
7. Sogn, J. A. 1998. Tumor immunology: the glass is half full. Immunity 9:757.
8. Graham, F. L., and L. Prevec. 1996. Gene transfer and expression protocols. In Methods in Molecular Biology. E. J. Murray, ed. Humana Press, Clifton, p. 109.
9. Coughin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, F. Liao, J. M. Farber, S. Petska, G. Trinchieri, and W. M. F. Lee. 1998. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25.
10. 3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat. Med. 4:408.
11. Lampson, L. A. 1995. Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Microsc. Res. Tech. 32: 267.
12. Friesel, R., A. Komoriya, and T. Maciag. 1987. Inhibition of endothelial cell proliferation by γ-interferon. J. Cell Biol. 104:689.
13. Brouty-Boye, D., and B. R. Zetter. 1980. Inhibition of cell motility by interferon. Science 208:516.
14. Sidky, Y. A., and E. C. Borden. 1987. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47: 5155.
15. Saiki, I., K. Sato, Y. C. Yoo, J. Murata, J. Yoneda, M. Kiso, A. Hasegawa, and I. Azuma. 1992. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-γ followed by a synthetic lipid-A subunit analogue (GLA-60). Int. J. Cancer. 51:641.
16. Maheshwari, R. K., V. Srikantan, D. Bhartiya, H. K. Kleinman, and D. S. Grant. 1991. Differential effects of interferon γ and α on in vitro model of angiogenesis. J. Cell. Physiol. 146:164.
17. Boehm, T., J. Folkman, T. Browder, and M. S. O'Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404.
18. Strieter, R. M., P. J. Polverini, D. A. Arenberg, and S. L. Kinkel. 1995. The role of CXC chemokines as regulators of angiogenesis. Shock 4:155.